发明名称 ENZYME INHIBITORS
摘要 <p>Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2is the side chain of a natural or non-natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(O)NR3-, -C(=S)-NR3 , -C(=NH)NR3 or -S(=O)2NR3-wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1 , Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula -X2-Q1- or -Q1-X2- wherein X2 is -O-, S- or NRA- wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, AIk1 and AIk2 independently represent optionally substituted divalent C3-C7 cycloalkyl radicals, or optionally substituted straight or branched, C1-C6 alkylene, C2-C6 alkenylene ,or C2-C6 alkynylene radicals which may optionally contain or terminate in an ether (-O-), thioether (-S-) or amino (-NRA-) link wherein RA is hydrogen or optionally substituted C1-C3 alkyl; X1 represents a bond; -C(=O); or -S(=O)2-; -NR4C(=O)-, -C(=O)NR4-, -NR4C(=O)NR5- , -NR4S(=O)2-, or -S(=O)2NR4-wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; z is 0 or 1 ; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R1R2NH-Y-L1-X1-[CH2]Z- and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.</p>
申请公布号 CA2599411(C) 申请公布日期 2013.12.03
申请号 CA20062599411 申请日期 2006.05.04
申请人 CHROMA THERAPEUTICS LTD. 发明人 DAVIDSON, ALAN HORNSBY;PATEL, SANJAY RATILAL;MAZZEI, FRANCESCA ANN;DAVIES, STEPHEN JOHN;DRUMMOND, ALAN HASTINGS;MOFFAT, DAVID FESTUS CHARLES;BAKER, KENNETH WILLIAM JOHN;DONALD, ALISTAIR DAVID GRAHAM
分类号 C07D487/04;A61K31/4045;A61K31/4353;A61K31/4965;A61P35/00;C07C259/06;C07C275/24;C07C311/46;C07D207/40;C07D207/416;C07D209/42;C07D213/40;C07D217/02;C07D217/12;C07D217/22;C07D295/18;C07D295/185;C07D333/62;C07D333/70;C07D471/04 主分类号 C07D487/04
代理机构 代理人
主权项
地址